The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials

The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials

Abstract Background Tislelizumab is an anti-programmed death-1 (PD-1) monoclonal antibody with a construction that enables it to have a higher affinity to its target. We aimed to evaluate tislelizumab’s safety and efficacy for treating non-small cell lung cancer (NSCLC). Methods Embase, Scopus, PubM...

Full description

Bibliographic Details
Main Authors: Amin Daei Sorkhabi, Mahta ZareDini, Asra Fazlollahi, Aila Sarkesh, Amirreza Naseri, Seyed Ehsan Mousavi, Seyed Aria Nejadghaderi, Mark J M Sullman, Ali-Asghar Kolahi, Saeid Safiri
Format: Article
Language:English
Published: BMC 2023-12-01
Series:BMC Pulmonary Medicine
Subjects:
Tislelizumab
Anti-PD-1 monoclonal antibody
Immune checkpoint inhibitors
NSCLC
Lung Cancer
Systematic review
Online Access:https://doi.org/10.1186/s12890-023-02755-3

Internet

https://doi.org/10.1186/s12890-023-02755-3

Similar Items